MorphoSys to Present at Five Investor Conferences in June
(Thomson Reuters ONE) -
MorphoSys AG /
MorphoSys to Present at Five Investor Conferences in June
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
The management of MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) will
present at five upcoming international investor conferences:
Jefferies 2013 Global Healthcare Conference
Date: June 6, 2013, 10:30am EDT (04:30pm CEST, 03:30pm BST)
Venue: New York, USA
Participants: Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG,
Dr. Claudia Gutjahr-Löser, Head of Corporate Communications & Investor Relations
Commerzbank Corporate Day
Date: June 6, 2013
Venue: London, UK
Participant: Jens Holstein, Chief Financial Officer of MorphoSys AG
6th DVFA Life Science Conference
Date: June 18, 2013
Venue: Frankfurt, Germany
Participants: Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG,
Dr. Claudia Gutjahr-Löser, Head of Corporate Communications & Investor Relations
Citi's European Healthcare Conference
Date: June 18, 2013
Venue: London, UK
Participant: Jens Holstein, Chief Financial Officer of MorphoSys AG
J.P. Morgan Cazenove European Healthcare Conference
Date: June 24, 2013, 04:00pm BST (05:00pm CEST, 11:00am EDT)
Venue: London, UK
Participants: Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG,
Dr. Claudia Gutjahr-Löser, Head of Corporate Communications & Investor Relations
The PDF version of the presentation will be provided at www.morphosys.com. The
link to the webcast will be filed under www.morphosys.com/conference-calls.
About MorphoSys:
MorphoSys developed HuCAL, the most successful antibody library technology in
the pharmaceutical industry. By successfully applying this and other patented
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human healthcare.
Together with its pharmaceutical partners, MorphoSys has built a therapeutic
pipeline of more than 70 human antibody drug candidates for the treatment of
cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few. With
its ongoing commitment to new antibody technology and drug development,
MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys is
listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates
about MorphoSys, visit http://www.morphosys.com.
HuCAL(®), HuCAL GOLD(®), HuCAL PLATINUM(®), CysDisplay(®), RapMAT(®), arYla(®),
Ylanthia(®) and 100 billion high potentials(®) are registered trademarks of
MorphoSys AG.
Slonomics(®) is a registered trademark of Sloning BioTechnology GmbH, a
subsidiary of MorphoSys AG.
This communication contains certain forward-looking statements concerning the
MorphoSys group of companies. The forward-looking statements contained herein
represent the judgment of MorphoSys as of the date of this release and involve
risks and uncertainties. Should actual conditions differ from the Company's
assumptions, actual results and actions may differ from those anticipated.
MorphoSys does not intend to update any of these forward-looking statements as
far as the wording of the relevant press release is concerned.
For more information, please contact:
MorphoSys AG
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-122
Mario Brkulj
Associate Director Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-454
Alexandra Goller
Specialist Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-332
investors(at)morphosys.com
Media Release (PDF):
http://hugin.info/130295/R/1706630/564980.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: MorphoSys AG via Thomson Reuters ONE
[HUG#1706630]
Unternehmensinformation / Kurzprofil:
Datum: 03.06.2013 - 17:01 Uhr
Sprache: Deutsch
News-ID 265869
Anzahl Zeichen: 4806
contact information:
Town:
Martinsried / München
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 122 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"MorphoSys to Present at Five Investor Conferences in June"
steht unter der journalistisch-redaktionellen Verantwortung von
MorphoSys AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
